371 related articles for article (PubMed ID: 29627952)
21. Clinical implications of DNA methylation-based integrated classification of histologically defined grade 2 meningiomas.
Ehret F; Perez E; Teichmann D; Meier S; Geiler C; Zeus C; Franke H; Roohani S; Wasilewski D; Onken J; Vajkoczy P; Schweizer L; Kaul D; Capper D
Acta Neuropathol Commun; 2024 May; 12(1):74. PubMed ID: 38720399
[TBL] [Abstract][Full Text] [Related]
22. DNA methylation analysis of benign and atypical meningiomas: correlation between RUNX3 methylation and WHO grade.
Majchrzak-Celińska A; Paluszczak J; Szalata M; Barciszewska AM; Nowak S; Baer-Dubowska W
J Cancer Res Clin Oncol; 2015 Sep; 141(9):1593-601. PubMed ID: 25648363
[TBL] [Abstract][Full Text] [Related]
23. Comprehensive genetic and epigenetic analysis of sporadic meningioma for macro-mutations on 22q and micro-mutations within the NF2 locus.
Hansson CM; Buckley PG; Grigelioniene G; Piotrowski A; Hellström AR; Mantripragada K; Jarbo C; Mathiesen T; Dumanski JP
BMC Genomics; 2007 Jan; 8():16. PubMed ID: 17222329
[TBL] [Abstract][Full Text] [Related]
24. [MOLECULAR PATHOLOGY OF MENINGIOMAS].
Murnyák B; Csonka T; Hortobágyi T
Ideggyogy Sz; 2015 Sep; 68(9-10):292-300. PubMed ID: 26665490
[TBL] [Abstract][Full Text] [Related]
25. The expression of fatty acid metabolism-associated proteins is correlated with the prognosis of meningiomas.
Jiang J; Lin C; Liu N; Zhang Z; Sun Y; Fang X; Qi J
APMIS; 2013 Oct; 121(10):997-1003. PubMed ID: 23879478
[TBL] [Abstract][Full Text] [Related]
26. Transcriptomic analysis of aggressive meningiomas identifies PTTG1 and LEPR as prognostic biomarkers independent of WHO grade.
Schmidt M; Mock A; Jungk C; Sahm F; Ull AT; Warta R; Lamszus K; Gousias K; Ketter R; Roesch S; Rapp C; Schefzyk S; Urbschat S; Lahrmann B; Kessler AF; Löhr M; Senft C; Grabe N; Reuss D; Beckhove P; Westphal M; von Deimling A; Unterberg A; Simon M; Herold-Mende C
Oncotarget; 2016 Mar; 7(12):14551-68. PubMed ID: 26894859
[TBL] [Abstract][Full Text] [Related]
27. Prognostic Value of Histopathological Features and Loss of H3K27me3 Immunolabeling in Anaplastic Meningioma: A Multicenter Retrospective Study.
Gauchotte G; Peyre M; Pouget C; Cazals-Hatem D; Polivka M; Rech F; Varlet P; Loiseau H; Lacomme S; Mokhtari K; Kalamarides M; Bielle F
J Neuropathol Exp Neurol; 2020 Jul; 79(7):754-762. PubMed ID: 32447376
[TBL] [Abstract][Full Text] [Related]
28. Integrative genomic analysis identifies CCNB1 and CDC2 as candidate genes associated with meningioma recurrence.
Bie L; Zhao G; Ju Y; Zhang B
Cancer Genet; 2011 Oct; 204(10):536-40. PubMed ID: 22137483
[TBL] [Abstract][Full Text] [Related]
29. Gene expression profiles of metabolic aggressiveness and tumor recurrence in benign meningioma.
Serna E; Morales JM; Mata M; Gonzalez-Darder J; San Miguel T; Gil-Benso R; Lopez-Gines C; Cerda-Nicolas M; Monleon D
PLoS One; 2013; 8(6):e67291. PubMed ID: 23840654
[TBL] [Abstract][Full Text] [Related]
30. DNA methylation profiling of meningiomas highlights clinically distinct molecular subgroups.
Singh J; Sharma R; Shukla N; Narwal P; Katiyar A; Mahajan S; Sahu S; Garg A; Sharma MC; Suri A; Sarkar C; Suri V
J Neurooncol; 2023 Jan; 161(2):339-356. PubMed ID: 36564673
[TBL] [Abstract][Full Text] [Related]
31. De novo and secondary anaplastic meningiomas: a study of clinical and histomolecular prognostic factors.
Peyre M; Gauchotte G; Giry M; Froehlich S; Pallud J; Graillon T; Bielle F; Cazals-Hatem D; Varlet P; Figarella-Branger D; Loiseau H; Kalamarides M
Neuro Oncol; 2018 Jul; 20(8):1113-1121. PubMed ID: 29216385
[TBL] [Abstract][Full Text] [Related]
32. TERT promoter mutation is associated with worse prognosis in WHO grade II and III meningiomas.
Biczok A; Kraus T; Suchorska B; Terpolilli NA; Thorsteinsdottir J; Giese A; Tonn JC; Schichor C
J Neurooncol; 2018 Sep; 139(3):671-678. PubMed ID: 29808339
[TBL] [Abstract][Full Text] [Related]
33. Integrative genomic analysis identifies NDRG2 as a candidate tumor suppressor gene frequently inactivated in clinically aggressive meningioma.
Lusis EA; Watson MA; Chicoine MR; Lyman M; Roerig P; Reifenberger G; Gutmann DH; Perry A
Cancer Res; 2005 Aug; 65(16):7121-6. PubMed ID: 16103061
[TBL] [Abstract][Full Text] [Related]
34. Methylation markers of malignant potential in meningiomas.
Vengoechea J; Sloan AE; Chen Y; Guan X; Ostrom QT; Kerstetter A; Capella D; Cohen ML; Wolinsky Y; Devine K; Selman W; Barnett GH; Warnick RE; McPherson C; Chiocca EA; Elder JB; Barnholtz-Sloan JS
J Neurosurg; 2013 Oct; 119(4):899-906. PubMed ID: 23930849
[TBL] [Abstract][Full Text] [Related]
35. TERT Promoter Mutations and Risk of Recurrence in Meningioma.
Sahm F; Schrimpf D; Olar A; Koelsche C; Reuss D; Bissel J; Kratz A; Capper D; Schefzyk S; Hielscher T; Wang Q; Sulman EP; Adeberg S; Koch A; Okuducu AF; Brehmer S; Schittenhelm J; Becker A; Brokinkel B; Schmidt M; Ull T; Gousias K; Kessler AF; Lamszus K; Debus J; Mawrin C; Kim YJ; Simon M; Ketter R; Paulus W; Aldape KD; Herold-Mende C; von Deimling A
J Natl Cancer Inst; 2016 May; 108(5):. PubMed ID: 26668184
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of 1p and 14q status, MIB-1 labeling index and progesterone receptor immunoexpression in meningiomas: Adjuncts to histopathological grading and predictors of aggressive behavior.
Kumar S; Kakkar A; Suri V; Kumar A; Bhagat U; Sharma MC; Singh M; Suri A; Sarkar C
Neurol India; 2014; 62(4):376-82. PubMed ID: 25237942
[TBL] [Abstract][Full Text] [Related]
37. The Emerging Relevance of H3K27 Trimethylation Loss in Meningioma: A Systematic Review of Recurrence and Overall Survival with Meta-Analysis.
Lu VM; Luther EM; Eichberg DG; Morell AA; Shah AH; Komotar RJ; Ivan ME
World Neurosurg; 2022 Jul; 163():87-95.e1. PubMed ID: 35439620
[TBL] [Abstract][Full Text] [Related]
38. Decrease in serine protease HtrA1 expression correlates with grade and recurrence in meningiomas.
Önder E; Arıkök AT; Seçkin H; Alper M
Adv Med Sci; 2015 Mar; 60(1):139-43. PubMed ID: 25687108
[TBL] [Abstract][Full Text] [Related]
39. Loss of H3K27me3 in WHO grade 3 meningioma.
Maier AD; Brøchner CB; Mirian C; Haslund-Vinding J; Bartek J; Ekström TJ; Poulsen FR; Scheie D; Mathiesen T
Brain Tumor Pathol; 2022 Oct; 39(4):200-209. PubMed ID: 35678886
[TBL] [Abstract][Full Text] [Related]
40. Immunocytochemical analysis of glucose transporter protein-1 (GLUT-1) in typical, brain invasive, atypical and anaplastic meningioma.
van de Nes JA; Griewank KG; Schmid KW; Grabellus F
Neuropathology; 2015 Feb; 35(1):24-36. PubMed ID: 25168354
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]